A case of six year survival with combined immunotherapy and antiangiogenesis for refractory ccRCC with brain metastasis

Imagine your body as a bustling city, and a cancer called clear cell renal cell carcinoma (ccRCC) as a very stubborn, invasive gang taking over the water treatment plant (the kidney). Usually, when this gang spreads to other parts of the city—like the lungs or, even worse, the brain—it's a race against the clock. For patients with brain invasions, the "natural" timeline before things get really bad is often less than three months. It's like a fire that spreads so fast that most firefighters give up after a few weeks.

But here is the story of one very special 49-year-old man who managed to stay in the game for a full 6 years. That's right, 6 years from his first diagnosis in April 2018 to his last check-up in April 2025.

The Battle Plan: A Game of "Whack-a-Mole"

This patient's journey wasn't a straight line; it was more like a high-stakes game of whack-a-mole where the moles kept popping up in new, tricky spots.

1. First Move (The Surgery and the First Shield): In April 2018, doctors removed the main tumor from his kidney. Then, they tried a targeted drug called sorafenib. Think of this drug as a specialized shield that blocks the gang's supply lines. It worked surprisingly well! The patient stayed stable for 41 months—that's over three years! This was much longer than the usual 5 to 8 months seen in similar cases, suggesting his tumor was a bit slower and more sensitive to this specific shield than most.

2. The Breakthrough (The Brain Attack): By November 2022, the gang got sneaky. They broke through the city's defenses and set up camp in the brain (specifically the right frontal lobe) and grew bigger in the lungs. The first shield stopped working.

3. Second Move (The Laser and the Double Team): Doctors tried a new strategy. They used a super-precise laser (radiation therapy) to zap the brain tumors while simultaneously giving a different drug, sunitinib, plus a booster called IL-2 to wake up the body's immune police. This worked for a while, but by April 2023, the gang was back, growing again. This second attempt only lasted 4 months.

4. Third Move (The Switch-Up): They tried a new combo: bevacizumab (a drug that cuts off blood supply to the gang) and camrelizumab (a drug that takes the "off switch" off the immune system). This held the line for 9 months, shrinking some tumors, but by January 2024, the gang was advancing again, this time in the left side of the brain.

5. The Winning Combo (The Fourth Line): This is where the magic happened. The doctors swapped the immune drug for tislelizumab but kept the blood-supply cutter (bevacizumab). They gave this combo every 3 weeks.

   • The Result: The tumors in the lungs and brain started to shrink! The doctors called this a "partial response." Even when a tiny spot in the brain grew slightly in December 2024, they kept the plan going.
   • The Outcome: By April 2025, the patient was still going strong, feeling good, with no major pain or dizziness. He had survived 6 years total.

Why Did This Work? (The Secret Sauce)

The authors suggest that this success wasn't just luck; it was a perfect storm of three things:

• The Team-Up: The paper argues that bevacizumab (the blood-supply cutter) and tislelizumab (the immune booster) work better together than alone. Imagine bevacizumab as a construction crew that removes the "no-entry" signs around the tumor, making it easier for the immune system's police (activated by tislelizumab) to get in and do their job. This "synergy" is what kept the disease under control for over 24 months after the patient had already failed two other lines of treatment.
• The Tumor's Personality: The patient's tumor had a "growth meter" (Ki-67) of only 10%–20%. This is lower than average for this type of cancer, meaning the gang wasn't moving as fast as usual, giving the treatments a better chance to catch them.
• The Patient's Stamina: The patient stayed healthy enough to keep taking the meds without needing to stop or lower the dose.

The Bumps in the Road

Even with this success, it wasn't a smooth ride. In March 2024, the patient had a seizure (a "secondary epilepsy" event) because of the brain tumors. Doctors treated this with a seizure medicine (sodium valproate), and the seizures stopped completely within 2 weeks. Crucially, they didn't have to stop the cancer treatment. The only other side effects were mild tiredness (grade 1 fatigue) and a mild skin reaction from earlier drugs. No severe, life-threatening side effects (grade 3 or higher) occurred.

What This Paper Doesn't Say

It's important to know what this story doesn't prove. The authors are very careful to say this is just one patient's story. They explicitly state that you cannot assume this will work for everyone with this cancer, especially since this patient had a unique, slow-growing tumor and hadn't tried immune drugs before.

• They did not test the patient's DNA or check for specific protein markers (like PD-L1) to explain exactly why the drugs worked, so the "molecular reason" is still a mystery.
• They did not run a giant study with hundreds of people to prove this is the new standard. This is a "case report," which is like a detailed diary entry, not a final rulebook.
• They suggest that while this looks promising, we need future large studies to confirm if this combo is truly the best choice for all patients who have failed other treatments.

The Bottom Line

For a patient with a very tough, drug-resistant kidney cancer that had spread to the brain, combining an immune-checkpoint inhibitor (like tislelizumab) with an anti-angiogenic drug (like bevacizumab) offered a way to control the disease for years when other options had failed. It suggests that this "tag-team" approach can turn a short, hopeless timeline into a long, manageable one, but the authors remind us that we need more data to be sure it works for everyone.